China’s pharmaceutical industry maintained stable demand fundamentals in the first half of 2026 (“1H2026”). The operating revenue of pharmaceutical manufacturers above designated size edged down year-on-year (“y-o-y”), while their total profit stabilized and recovered slightly. Chinese innovative drug companies were highly active in out-licensing transactions, with deal value hitting a record high for the same period in history.